Prot# 2401BT-002P: A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) with Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma

Project: Research project

Project Details

StatusActive
Effective start/end date1/12/181/12/21

Funding

  • DNAtrix, Inc. (Prot# 2401BT-002P)